SEHK:2171Biotechs
A Fresh Look at CARsgen Therapeutics (SEHK:2171) Valuation After New CAR-T Trial Data Release
CARsgen Therapeutics Holdings (SEHK:2171) just shared clinical trial data on two of its allogeneic CAR-T cell therapies for heavily pretreated blood cancers. The results suggest progress and could bring renewed investor focus to the company’s pipeline.
See our latest analysis for CARsgen Therapeutics Holdings.
CARsgen’s positive clinical updates are catching attention, especially with the stock posting a 68% year-to-date share price return and an impressive 109% total shareholder return over...